Form 4: BIOCRYST Director Amy McKee Acquires Shares

BIOCRYST PHARMACEUTICALS Director Amy E McKee acquired 642 shares of common stock on February 27, 2026, as part of her board compensation.

Summary

• Amy E McKee, a Director of BIOCRYST PHARMACEUTICALS INC (BCRX), acquired 642 shares of common stock.
• The transaction occurred on February 27, 2026, at a price of $8.75 per share.
• These shares were issued in lieu of 50% of her quarterly cash Board Member retainer, which is $11,250.
• Following this transaction, Ms. McKee directly beneficially owns 42,432 shares of BIOCRYST PHARMACEUTICALS common stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a director increasing their stake, even through compensation, generally indicates confidence in the company's future and aligns management interests with shareholders.

Positives

• A director is increasing her direct ownership in the company, which can signal confidence in the company's future prospects.
• The acquisition of shares as part of compensation aligns the director's interests with those of shareholders.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that insider purchases, even those related to compensation, are generally viewed positively by the market as they indicate management's belief in the company's value and future performance. While this is a relatively small transaction, it contributes to the overall picture of insider alignment with shareholder interests within the biotechnology sector.

Comparison to Industry Standards

• This transaction is a standard practice for director compensation, where a portion of the retainer is paid in equity to align interests.
• Many companies across various industries, including biotechnology, utilize similar equity-based compensation structures for their board members.
• For example, directors at peer biotech companies like Regeneron Pharmaceuticals or Amgen often receive a significant portion of their compensation in restricted stock units or stock options, reinforcing long-term commitment.

Related Party Transactions

• The acquisition of shares by Director Amy E McKee as part of her board compensation constitutes a related party transaction, as it involves a transaction between the company and a member of its board of directors.

Stakeholder Impact

• Shareholders: The transaction may be viewed positively by shareholders as it demonstrates increased alignment of a director's interests with their own, potentially signaling confidence in the company's long-term value.
• Employees: No direct impact on employees is indicated by this filing.
• Customers: No direct impact on customers is indicated by this filing.
• Suppliers: No direct impact on suppliers is indicated by this filing.
• Creditors: No direct impact on creditors is indicated by this filing.

Key Dates

Keywords

BIOCRYST PHARMACEUTICALS, BCRX, Amy E McKee, Director, Insider Trading, Form 4, Stock Acquisition, Common Stock, Board Compensation